SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

LONA

LeonaBio, Inc.
NASDAQHealth Care

Latest close: 5.20 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 22, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 26, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 14, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record42324 flagged findings
Reported transactions (Form 4)80since Jan 2, 2025 · and 11 other holdings
Corporate events (8-K)23since Dec 14, 2020

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

Identity

Formerly traded as ATHA.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-07share offering or dilution eventrecentOpen filing ↗
    “…convertible preferred stock, common stock warrants, prefunded common stock warrants and convertible notes, and to a lesser extent…”
    +1 more passage from the same document
    • “…convertible notes, and to a lesser extent from grant income and stock option exercises. From our inception through March 31, 2026, we…”
  • 2026-05-07capital return (buybacks/dividends)recentOpen filing ↗
    “…settled in the Company’s equity shares is evaluated under ASC 480, Distinguishing Liabilities from Equity , to determine proper…”
  • 2026-04-02share offering or dilution eventrecentOpen filing ↗
    “…Warrants”) and (4) warrants to purchase 21,259,842 shares of our common stock and/or pre-funded warrants (the “PIPE Series B Common…”
    +1 more passage from the same document
    • “…different number for subject enrollment in a protocol amendment and (c) the date on which the FDA approves or issues a complete…”
  • 2026-04-02share offering or dilution eventrecentOpen filing ↗
    “…by and between us and Sermonix, pursuant to which Sermonix granted us an exclusive license to develop, manufacture,…”
    +1 more passage from the same document
    • “…granted us an exclusive license to develop, manufacture, commercialize and otherwise exploit products containing lasofoxifene in…”
  • 2026-03-31share offering or dilution eventrecentOpen filing ↗
    “…in the future. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee,…”
    +1 more passage from the same document
    • “…stock, common stock warrants, prefunded common stock warrants and convertible notes, and to a lesser extent from grant income…”
  • 2026-03-31listing compliance noticerecentOpen filing ↗
    “…or otherwise. Any such future issuance, including any additional issuances pursuant to our “at-the-market” equity offering…”
    +1 more passage from the same document
    • “…cause our stock price to decline. Our reverse stock split to regain compliance with the Nasdaq Capital Market Minimum Bid…”
  • 2026-03-31capital return (buybacks/dividends)recentOpen filing ↗
    “…settled in the Company’s equity shares is evaluated under ASC 480, Distinguishing Liabilities from Equity , to determine proper…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:10 on Sep 18, 2025) · 1:10 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 423)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 22, 268-K ↗Current report · Other events
  • Sep 3, 26Form 3 ↗Insider transaction
  • Aug 31, 26SCHEDULE 13D ↗Stake with intent to influence · Sermonix Pharmaceuticals, Inc. · 36.9% · event on Aug 24, 26
  • Aug 26, 268-K ↗Current report · Other events
  • Aug 25, 26SCHEDULE 13D/A ↗Stake with intent to influence · Perceptive Advisors LLC · 20.0% · event on Aug 22, 26 · amendment
  • Aug 20, 26SCHEDULE 13G/A ↗Passive stake · Anders Hove · 12.1% · event on Aug 18, 26 · amendment
  • Aug 14, 2610-Q ↗Quarterly report
  • Aug 14, 268-K ↗Current report · Results · Communication to the market
  • Insider transaction · 11 Form 4 filingsshow all 11hide
  • Jun 23, 268-K ↗Current report · Shareholder vote results
  • May 15, 26SCHEDULE 13G ↗Passive stake · ADAR1 Capital Management, LLC · 7.7% · event on Mar 31, 26
  • May 11, 26DEFA14A ↗Shareholder meeting and votes
  • May 11, 26DEF 14A ↗Shareholder meeting and votes
  • May 7, 26Form 4 ↗Insider transaction
  • May 7, 26Form 3 ↗Insider transaction

423 filings on record, the oldest from Aug 21, 20.

Listing the 25 most recent filings of the 423 on record.

8-Ks, explained

Stress3Structure6Governance14
  • Mar 31, 26StructureCompleted an acquisition or disposal+1 more in the same filing8-K/A 2.01 ↗
  • Mar 19, 26GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Jan 9, 26GovernanceA senior executive left or was appointed+4 more in the same filing8-K 5.02 ↗
  • Dec 18, 25StructureEntered a material agreement+4 more in the same filing8-K/A 1.01 ↗
  • Dec 18, 25StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Apr 16, 25StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Oct 18, 24StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Oct 7, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Sep 17, 24StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Governance3 senior executive changes2023 – 2024show all 3hide
    • Feb 22, 24GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
    • Jan 8, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • May 22, 23GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Jan 6, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance7 senior executive changes2020 – 2022show all 7hide
    • Mar 21, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jan 31, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Oct 21, 21GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jun 21, 21GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Mar 8, 21GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jan 11, 21GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Dec 14, 20GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Sermonix Pharmaceuticals, Inc.36.9%Aug 24, 26SCHEDULE 13D ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Joseph Edelman20.1%Dec 23, 25SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Perceptive Advisors LLC20.0%Aug 22, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Anders Hove12.1%Aug 18, 26SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
  • Leonard Braden Michael7.8%Dec 31, 24SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • ADAR1 Capital Management, LLC7.7%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Steven Michael Oliveira5.1%Apr 14, 25SCHEDULE 13G ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • Oliveira Steven Michael4.1%Oct 1, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
show one more holderhide
  • Baselake Partners, LP1.9%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Mar 4, 26Sell$28KMark James LittonPRESIDENT and CEO↗
  • Mar 4, 26Sell$9KMartin Javier SanCHIEF MEDICAL OFFICER↗
  • Mar 4, 26Sell$7KKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • Mar 4, 26Sell$7KMark WorthingtonGENERAL COUNSEL and CCO↗
  • Mar 4, 26Sell$5KRobert RenningerCHIEF FINANCIAL OFFICER↗
  • Jan 2, 26Sell$18KMark James LittonPresident and CEO↗
  • Jan 2, 26Sell$11KMartin Javier SanCHIEF MEDICAL OFFICER↗
  • Jan 2, 26Sell$6KKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • Jan 2, 26Sell$6KMark WorthingtonGeneral Counsel and CCO↗
  • Jan 2, 26Sell$2KRobert RenningerChief Financial Officer↗
  • Jul 1, 25Sell$850Robert RenningerSVP, Finance and Accounting↗
  • Jul 1, 25Sell$3KMark WorthingtonGeneral Counsel and CCO↗

There are 7 more transactions in this stretch.

Stock compensation, tax and giftsshow the 21 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Mar 3, 26Compensationamount n/aMark James LittonPRESIDENT and CEO↗
  • Mar 3, 26Compensationamount n/aMartin Javier SanCHIEF MEDICAL OFFICER↗
  • Mar 3, 26Compensationamount n/aKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • Mar 3, 26Compensationamount n/aMark WorthingtonGENERAL COUNSEL and CCO↗
  • Mar 3, 26Compensationamount n/aRobert RenningerCHIEF FINANCIAL OFFICER↗
  • Dec 31, 25Compensationamount n/aMark James LittonPresident and CEO↗
  • Dec 31, 25Compensationamount n/aMartin Javier SanCHIEF MEDICAL OFFICER↗
  • Dec 31, 25Compensationamount n/aKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • Dec 31, 25Compensationamount n/aMark WorthingtonGeneral Counsel and CCO↗
  • Dec 31, 25Compensationamount n/aRobert RenningerChief Financial Officer↗
  • Dec 23, 25Compensation$6.3MPERCEPTIVE ADVISORS LLC↗
  • Dec 23, 25Compensation$2.1MPERCEPTIVE ADVISORS LLC↗
  • Nov 18, 25Compensation$2KKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • Nov 18, 25Compensation$2KRobert RenningerChief Financial Officer↗
  • Jun 30, 25Compensationamount n/aRobert RenningerSVP, Finance and Accounting↗
  • Jun 30, 25Compensationamount n/aMark WorthingtonGeneral Counsel and CCO↗
  • Jun 30, 25Compensationamount n/aMartin Javier SanCHIEF MEDICAL OFFICER↗
  • Jun 30, 25Compensationamount n/aMark James LittonPresident and CEO↗
  • Jun 30, 25Compensationamount n/aKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗
  • May 19, 25Compensation$2KRobert RenningerSVP, Finance and Accounting↗
  • May 19, 25Compensation$2KKEVIN CHURCHCHIEF SCIENTIFIC OFFICER↗

The full record holds 103 transactions and goes back to Nov 18, 22.

Its sector and its market

LeonaBio, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From LeonaBio, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow LeonaBio, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
423 documents on file, from Aug 21, 2020 to Sep 22, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.